| Literature DB >> 22085269 |
Akiko Nakayama1, Karen P Alladin, Obianuju Igbokwe, Jeffrey D White.
Abstract
The risk-benefit ratio for concurrent use of dietary antioxidants with chemotherapy or radiation therapy is a controversial topic. In this review, the medical literature on concurrent antioxidant use with chemotherapy or radiotherapy was assessed and further steps for generating evidence-based guidelines are suggested. The clinical cancer research community should cooperate and focus new studies on the use of a specific combination of antioxidant and chemotherapy or radiotherapy, and determine optimal doses for a specific cancer setting. Mechanistic studies on the interaction between antioxidants and conventional cancer therapy could lead to novel biomarkers for assessing dose adequacy.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22085269 PMCID: PMC3666569 DOI: 10.3109/07357907.2011.626479
Source DB: PubMed Journal: Cancer Invest ISSN: 0735-7907 Impact factor: 2.176